<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE303nnn/GSE303181/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303181</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>STC-1 Attenuates Scar Formation via PI3K/AKT Pathway Activation and Immune Modulation</name><description>Objective: To investigate the role of Stanniocalcin-1 (STC-1) in scar formation and elucidate its underlying mechanisms in regulating fibroblast activity, immune microenvironment, oxidative stress, and PI3K/AKT signaling. Approach: A combination of clinical sample analysis, in vitro experiments using NIH-3T3 fibroblasts and macrophage co-culture models, RNA sequencing, and in vivo full-thickness wound mouse models were employed. The effects of recombinant human STC-1 and STC-1 overexpression were evaluated on fibroblast function, extracellular matrix remodeling, inflammatory response, and scar formation. The impact on PI3K/AKT signaling was assessed by Western blot analysis. Results: STC-1 was specifically overexpressed in keloid tissues, primarily in fibroblasts, and its expression was upregulated by hypoxia in a HIF-1α–dependent manner. In vitro, STC-1 suppressed fibroblast proliferation, migration, and LPS-induced inflammation, while alleviating oxidative stress and mitochondrial dysfunction. STC-1 also promoted angiogenesis and induced M2 macrophage polarization. In vivo, STC-1 reduced scar size, improved collagen organization, modulated immune cell infiltration by activating the PI3K/AKT signaling pathway. Innovation: This study identifies STC-1 as a novel immunoregulatory and anti-fibrotic factor in scar pathogenesis. It highlights that STC-1 not only affects fibroblast function but also remodels the immune microenvironment through PI3K/AKT activation. Conclusion: STC-1 exerts anti-fibrotic, anti-inflammatory, antioxidant, and immunomodulatory effects during scar formation by activating the PI3K/AKT signaling pathway, highlighting its therapeutic potential in the treatment of pathological scars.</description><dates><publication>2026/08/01</publication></dates><accession>GSE303181</accession><cross_references><GSM>GSM9119920</GSM><GSM>GSM9119910</GSM><GSM>GSM9119919</GSM><GSM>GSM9119909</GSM><GSM>GSM9119917</GSM><GSM>GSM9119918</GSM><GSM>GSM9119915</GSM><GSM>GSM9119916</GSM><GSM>GSM9119913</GSM><GSM>GSM9119914</GSM><GSM>GSM9119911</GSM><GSM>GSM9119912</GSM><GPL>30215</GPL><GSE>303181</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>